Rarity Bioscience superRCA technology assays

Wednesday, 12 March, 2025 | Supplied by: Beckman Coulter Australia


As part of a co-exclusive distribution agreement, Beckman Coulter Life Sciences will market and distribute Rarity Bioscience’s superRCA technology assays. The assays are claimed to accelerate the detection of mutations by using flow cytometry with logarithmically higher sensitivity compared to the current gold standard digital PCR (dPCR) method.

While traditional flow cytometry research analyses phenotypes, the platform combines a molecular assay based on rolling circle amplification and padlock probes with a flow cytometry readout for high sensitivity and specific multiplex detection of sequence variants, including single point DNA mutations. The assay offers high throughput, resulting in fast turnaround without the need for additional hardware, lowering the barriers to molecular research assays.

Online: www.beckman.com.au
Phone: 1800 060 878
Related Products

Azure Biosystems Ao Microplate Reader

The 96-well Ao Microplate Reader from Azure Biosystems offers a multitude of features to help...

Navinci Naveni Plex isPLA multiplex solution

The isPLA multiplex solution is designed to simultaneously detect PD1/PD-L1 interactions...

PBL Assay Science Interferon ELISA Kits

PBL Assay Science's Interferon ELISA Kits are designed to be easily adopted in a regulated...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd